Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential of dietary polyphenols for protection from age-related decline and neurodegeneration: a role for gut microbiota?

Nutritional neuroscience·2024
Same author

Role of diet and its effects on the gut microbiome in the pathophysiology of mental disorders.

Translational psychiatry·2022
Same author

Correlates of 1-Year Change in Quality of Life in Patients with Urologic Chronic Pelvic Pain Syndrome: Findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.

The Journal of urology·2020
Same author

History of early life adversity is associated with increased food addiction and sex-specific alterations in reward network connectivity in obesity.

Obesity science & practice·2019
Same author

The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity.

Obesity science & practice·2017
Same author

Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response.

Neurogastroenterology and motility·2017

Related Experiment Video

Updated: Jul 10, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Functional GI disorders: from animal models to drug development.

E A Mayer1, S Bradesi, L Chang

  • 1UCLA Center for Neurovisceral Sciences & Women's Health, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA. emayer@ucla.edu

Gut
|October 30, 2007
PubMed
Summary

Developing new irritable bowel syndrome (IBS) treatments is challenging. Current models show limited predictive value, suggesting a need for revised drug development strategies focusing on imaging.

More Related Videos

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
06:01

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay
10:29

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay

Published on: April 14, 2014

Related Experiment Videos

Last Updated: Jul 10, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
06:01

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay
10:29

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay

Published on: April 14, 2014

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Translational Medicine

Background:

  • Drug development for functional gastrointestinal disorders, including irritable bowel syndrome (IBS), has yielded disappointing results.
  • Traditional methods rely on animal models, experimental medicine, and clinical trials, with limited success in predicting treatment efficacy.
  • Key IBS symptoms like abdominal pain, defecation issues, and psychological factors contribute to overall severity and quality of life impairment.

Purpose of the Study:

  • To review the empirical basis of current drug development models for IBS.
  • To assess the predictive validity of preclinical and clinical models for identifying effective IBS treatments.
  • To propose an alternative drug development algorithm for functional gastrointestinal disorders.

Main Methods:

  • Review of published evidence on visceral hypersensitivity and gastrointestinal transit in animal and human models.
  • Analysis of correlations between preclinical/clinical model readouts and IBS symptoms.
  • Evaluation of the predictive power of existing models for treatment success.

Main Results:

  • Correlations between model readouts and IBS symptoms are generally small.
  • The ability of current models to predict drug effectiveness for specific or global IBS symptoms is limited.
  • Abdominal pain, defecation symptoms, and psychological factors significantly impact IBS severity and quality of life.

Conclusions:

  • Current preclinical and clinical models have limited predictive validity for IBS drug development.
  • A revised algorithm prioritizing pharmacological imaging in preclinical and clinical settings is proposed.
  • Reduced reliance on symptom-based animal models and faster human screening may improve treatment discovery for IBS.